Collegium Pharmaceutical, Inc. (COLL)Â
NASDAQ$29.86-0.29 (-0.96%)
Market Cap
$949.29M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
525 of 919
Rank in Industry
26 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
COLL Insider Trading Activity
COLL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $13,007,446 | 25 | 100 |
Related Transactions
| Smith Thomas B | EVP and Chief Medical Officer | 0 | $0 | 1 | $351,320 | $-351,320 |
| BOHLIN GAREN G | director | 0 | $0 | 1 | $936,311 | $-936,311 |
| Tupper Colleen | EVP & Chief Financial Officer | 0 | $0 | 7 | $1.35M | $-1.35M |
| Kuhlmann Shirley R. | EVP and General Counsel | 0 | $0 | 7 | $4.92M | $-4.92M |
| Dreyer Scott | EVP & Chief Commercial Officer | 0 | $0 | 9 | $5.45M | $-5.45M |
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Activity of Collegium Pharmaceutical, Inc.
Over the last 12 months, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $13.01M worth of Collegium Pharmaceutical, Inc. stock.
On average, over the past 5 years, insiders at Collegium Pharmaceutical, Inc. have bought $0 and sold $8.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $183,600 was made by Brannelly Paul (Executive Vice President & CFO) on 2017‑05‑12.
List of Insider Buy and Sell Transactions, Collegium Pharmaceutical, Inc.
| 2025-03-21 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 6,396 0.0203% | $30.03 | $192,069 | +1.01% | |
| 2025-03-21 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 18,881 0.0599% | $30.03 | $566,983 | +1.01% | |
| 2025-03-20 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 1,206 0.0038% | $30.00 | $36,181 | +0.73% | |
| 2025-03-20 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 1,927 0.0061% | $30.00 | $57,811 | +0.73% | |
| 2025-03-14 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 977 0.0032% | $30.00 | $29,313 | +1.49% | |
| 2025-03-14 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 2,255 0.0073% | $30.00 | $67,661 | +1.49% | |
| 2025-03-11 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 10,445 0.0332% | $30.01 | $313,413 | -0.52% | |
| 2025-03-11 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 15,387 0.0489% | $30.00 | $461,672 | -0.52% | |
| 2025-03-07 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 1,504 0.005% | $30.00 | $45,121 | +3.22% | |
| 2025-03-07 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 2,348 0.0077% | $30.00 | $70,446 | +3.22% | |
| 2025-03-06 | Sale | Tupper Colleen | EVP & Chief Financial Officer | 1,949 0.0062% | $30.00 | $58,470 | -0.07% | |
| 2025-03-06 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 3,295 0.0105% | $30.00 | $98,854 | -0.07% | |
| 2025-03-06 | Sale | Dreyer Scott | EVP & Chief Commercial Officer | 15,387 0.0491% | $30.00 | $461,672 | -0.07% | |
| 2025-03-06 | Sale | Kuhlmann Shirley R. | EVP and General Counsel | 26,067 0.079% | $28.50 | $742,946 | -0.07% | |
| 2025-03-05 | Sale | Kuhlmann Shirley R. | EVP and General Counsel | 20,000 0.0628% | $28.03 | $560,528 | +4.67% | |
| 2025-03-04 | Sale | Kuhlmann Shirley R. | EVP and General Counsel | 40,000 0.1279% | $28.08 | $1.12M | +6.35% | |
| 2025-01-10 | Sale | Kuhlmann Shirley R. | EVP and General Counsel | 27,500 0.0865% | $33.04 | $908,628 | -8.49% | |
| 2024-09-13 | Sale | Smith Thomas B | EVP and Chief Medical Officer | 9,593 0.0291% | $36.62 | $351,320 | -17.60% | |
| 2024-09-06 | Sale | Kuhlmann Shirley R. | EVP and General Counsel | 977 0.0031% | $37.46 | $36,594 | -16.74% | |
| 2024-09-05 | Sale | Kuhlmann Shirley R. | EVP and General Counsel | 19,248 0.0608% | $38.30 | $737,198 | -17.65% |
Total: 131
*Gray background shows transactions not older than one year
Insider Historical Profitability
42.23%
| Tupper Colleen | EVP & Chief Financial Officer | 156667 0.4976% | $4.72M | 0 | 9 | |
| Kuhlmann Shirley R. | EVP and General Counsel | 108137 0.3435% | $3.26M | 0 | 15 | |
| Dreyer Scott | EVP & Chief Commercial Officer | 103613 0.3291% | $3.12M | 0 | 22 | |
| Smith Thomas B | EVP and Chief Medical Officer | 53816 0.1709% | $1.62M | 0 | 2 | |
| BOHLIN GAREN G | director | 44775 0.1422% | $1.35M | 0 | 1 | |
| Freund John Gordon | 2949916 9.3691% | $88.94M | 1 | 0 | +44.38% | |
| Skyline Venture Partners V LP | 10 percent owner | 2949916 9.3691% | $88.94M | 1 | 0 | +44.38% |
| Heron Patrick J | 1887332 5.9943% | $56.9M | 1 | 0 | +44.38% | |
| Frazier Healthcare VI, L.P. | 10 percent owner | 1887332 5.9943% | $56.9M | 1 | 0 | +44.38% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1325253 4.2091% | $39.96M | 1 | 0 | +44.38% | |
| Ciaffoni Joseph | President and CEO | 275000 0.8734% | $8.29M | 0 | 31 | |
| Fleming Alison B | Chief Technical Officer | 148753 0.4724% | $4.48M | 0 | 12 | |
| Brannelly Paul | Executive Vice President & CFO | 123436 0.392% | $3.72M | 1 | 1 | +42.57% |
| Longitude Capital Partners, LLC | 10 percent owner | 45620 0.1449% | $1.38M | 1 | 1 | +44.38% |
| Heffernan Michael Thomas | director | 28023 0.089% | $844,893.45 | 0 | 25 | |
| Hirsch David | director | 17117 0.0544% | $516,077.55 | 1 | 3 | +44.38% |
| Fallon John A. | director | 2375 0.0075% | $71,606.25 | 1 | 0 | +26.87% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$910,099,463 | 123 | 11.52% | $2.58B | |
$187,390,806 | 89 | 12.63% | $812.34M | |
$12,681,496 | 70 | 20.90% | $792.36M | |
$14,599,168 | 59 | 12.79% | $1.44B | |
$129,489,279 | 57 | 26.09% | $662.04M | |
$33,884,330 | 45 | 12.50% | $420.76M | |
$97,642,477 | 41 | -10.58% | $790.38M | |
$102,493,771 | 40 | 22.98% | $1.14B | |
$73,284,153 | 37 | -4.48% | $3.71B | |
$21,068,600 | 35 | 9.64% | $1.73B | |
$10,187,479 | 35 | 37.26% | $1.03B | |
$12,998,723 | 30 | 3.46% | $3.94B | |
$6,506,230 | 27 | -16.20% | $700.03M | |
$83,406,412 | 19 | 21.96% | $1.84B | |
$1,843,996 | 10 | 22.92% | $1.35B | |
Collegium Pharmaceutical, Inc. (COLL) | $26,633,903 | 9 | 42.23% | $949.29M |
$1,683,154 | 8 | 46.59% | $639.11M | |
$543,932 | 6 | -22.04% | $735.4M | |
$514,533 | 5 | 29.59% | $871.23M |
COLL Institutional Investors: Active Positions
| Increased Positions | 108 | +34.29% | 3M | +8.73% |
| Decreased Positions | 138 | -43.81% | 5M | -12.14% |
| New Positions | 36 | New | 594,788 | New |
| Sold Out Positions | 46 | Sold Out | 985,067 | Sold Out |
| Total Postitions | 285 | -9.52% | 37M | -3.42% |
COLL Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $166,946.00 | 17.92% | 5.56M | +35,784 | +0.65% | 2024-12-31 |
| Eventide Asset Management, Llc | $79,293.00 | 8.51% | 2.64M | +3,296 | +0.13% | 2024-12-31 |
| Rubric Capital Management Lp | $70,618.00 | 7.58% | 2.35M | +1M | +88% | 2024-12-31 |
| Vanguard Group Inc | $68,594.00 | 7.36% | 2.28M | -63,876 | -2.72% | 2024-12-31 |
| Pacer Advisors, Inc. | $64,382.00 | 6.91% | 2.14M | -447,157 | -17.27% | 2024-12-31 |
| Invesco Ltd. | $53,362.00 | 5.73% | 1.78M | +289,335 | +19.46% | 2024-12-31 |
| Renaissance Technologies Llc | $49,930.00 | 5.36% | 1.66M | +5,480 | +0.33% | 2024-12-31 |
| Principal Financial Group Inc | $49,434.00 | 5.31% | 1.65M | -100,767 | -5.77% | 2024-12-31 |
| State Street Corp | $43,186.00 | 4.64% | 1.44M | +63,828 | +4.65% | 2024-12-31 |
| Fuller & Thaler Asset Management, Inc. | $40,624.00 | 4.36% | 1.35M | -18,074 | -1.32% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.